Q3 FY2026 call
FetchingAmgen Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$465.73-0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Amgen discovers, makes and sells prescription medicines for serious diseases, along with biosimilar medicines.
Company outlook: revenue of $38.9B to $39.7B for Fiscal year 2026 — up 6.9% on a year earlier
Just reported
From Amgen Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$10.37B
+8.5% y/y
+3.1% q/q
Guided
—
No guide given
Actual
$7.08
+19% y/y
+62% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $10.4B | $9.6B | +8.45% |
| Profit | $3.9B | $3.2B | +20.15% |
| Profit per share | $7.08 | $5.93 | +19.39% |
| Free Cash Flow | $3.7B | $4.2B | -13.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Amgen Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Page 16 largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Amgen Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$3.71B
+47% y/y
+5.6% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Call summaries are part of Pro
A two-minute read of every Amgen Inc. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.